antibodies, monoclonal, Murine-Derived

Preferred Label : antibodies, monoclonal, Murine-Derived;

MeSH definition : Antibodies obtained from a single clone of cells grown in mice or rats.;

MeSH synonym : Murine-Derived monoclonal antibodies; antibodies, Murine-Derived monoclonal; monoclonal antibodies, Murine-Derived; murine derived monoclonal antibodies;

MeSH annotation : use when indicated in text; follow author's terminology;

Is substance : O;

Details

Origin ID

D058846;

UMLS CUI

C2916903;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- analysis [MeSH Qualifier]
- biosynthesis [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- drug effects [MeSH Qualifier]
- economics [MeSH Qualifier]
- genetics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- physiology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- ultrastructure [MeSH Qualifier]
- urine [MeSH Qualifier]
Record concept(s)
- antibodies, monoclonal, Murine-Derived [MeSH concept]
Related MeSH Supplementary Concept(s)
- 12C3 monoclonal antibody [MeSH Supplementary Concept]
- 131I-rituximab [MeSH Supplementary Concept]
- 177Lu-DOTA-rituximab [MeSH Supplementary Concept]
- 23C3 monoclonal antibody [MeSH Supplementary Concept]
- 3D6 antibody [MeSH Supplementary Concept]
- 3F8 antibody [MeSH Supplementary Concept]
- 64Cu-DOTA-rituximab [MeSH Supplementary Concept]
- 89Zr-rituximab [MeSH Supplementary Concept]
- 8H9 monoclonal antibody [MeSH Supplementary Concept]
- 9F7-F11 antibody [MeSH Supplementary Concept]
- AC12 monoclonal antibody [MeSH Supplementary Concept]
- CD44 monoclonal antibody KMP1 [MeSH Supplementary Concept]
- CT-P10 [MeSH Supplementary Concept]
- EP-5C7 monoclonal antibody [MeSH Supplementary Concept]
- K7153A [MeSH Supplementary Concept]
- LBY135 monoclonal antibody [MeSH Supplementary Concept]
- Lym-1 monoclonal antibody [MeSH Supplementary Concept]
- M290SAP [MeSH Supplementary Concept]
- MOv18 monoclonal antibody [MeSH Supplementary Concept]
- MX 35 monoclonal antibody [MeSH Supplementary Concept]
- Mab13-1 monoclonal antibody [MeSH Supplementary Concept]
- PF-06647263 [MeSH Supplementary Concept]
- PR1A3 monoclonal antibody [MeSH Supplementary Concept]
- R-CHOP protocol [MeSH Supplementary Concept]
- R-FCM protocol [MeSH Supplementary Concept]
- R21 monoclonal antibody [MeSH Supplementary Concept]
- RCK105 [MeSH Supplementary Concept]
- RG 83852 monoclonal antibody [MeSH Supplementary Concept]
- RIME regimen [MeSH Supplementary Concept]
- TOL-101 [MeSH Supplementary Concept]
- TSK114 monoclonal antibody [MeSH Supplementary Concept]
- abagovomab [MeSH Supplementary Concept]
- anti-Fas monoclonal antibody [MeSH Supplementary Concept]
- besilesomab [MeSH Supplementary Concept]
- edrecolomab [MeSH Supplementary Concept]
- enlimomab [MeSH Supplementary Concept]
- heavy chain, monoclonal antibody B23 [MeSH Supplementary Concept]
- monoclonal antibody 2P-1-2-1 [MeSH Supplementary Concept]
- monoclonal antibody D2-40 [MeSH Supplementary Concept]
- omburtamab I-131 [MeSH Supplementary Concept]
- oregovomab [MeSH Supplementary Concept]
- racotumomab [MeSH Supplementary Concept]
- rituximab-alliinase conjugate [MeSH Supplementary Concept]
- sulesomab [MeSH Supplementary Concept]
- technetium 99m carbonyl DTPA-rituximab [MeSH Supplementary Concept]
- technetium 99m rituximab [MeSH Supplementary Concept]
- technetium tc 99m CIBCNSH3 [MeSH Supplementary Concept]
- technetium tc 99m-monoclonal antibody-170H.82 [MeSH Supplementary Concept]
- technetium tc 99m-nofetumomab merpentan [MeSH Supplementary Concept]
- terbium-rituximab [MeSH Supplementary Concept]
- thorium-227-DOTA-rituximab [MeSH Supplementary Concept]
- thorium-4-benzyl-DOTA-rituximab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients